Many Firsts As Celltrion/Pfizer’s Inflectra Becomes Second US Biosimilar

Move over Zarxio, there's a new kid in town: Inflectra (infliximab-dyyb), which won the FDA's nod on April 5 as the first monoclonal antibody biosimilar licensed in the US, although it's going to be a while before patients have access to the new drug, since Celltrion and Pfizer said they won't put it on the market until after June 29.